I've been watching this GLP-1 drug narrative play out, and honestly, the market's gotten a bit carried away with Eli Lilly. Don't get me wrong - the company's doing impressive things with Mounjaro and Zepbound. Their weight-loss drug sales jumped 175% last year, and the diabetes treatment is up 99%. That's real momentum. But here's what concerns me: these two products basically ARE Eli Lilly's growth story right now. They represented 56% of the company's top line in 2025, which means if you strip those out, you're looking at a pretty ordinary pharma company.

The bigger issue? This won't last forever. Generic competition is coming. It always does in pharma. When Mounjaro and Zepbound face off against cheaper generics, the revenue cliff could be steep. Wall Street seems to be pricing in a perfect scenario where nothing goes wrong, and that's where I get nervous. The stock's trading at a P/E of 45, which is frankly expensive for a company betting everything on two drugs. Meanwhile, the dividend yield is sitting at just 0.6% - you're basically getting nothing for income.

So where do I look instead? Pfizer's been beaten down, and that's actually created an opportunity. Yeah, their internal GLP-1 drug candidate didn't work out. Drug failures happen - it's part of the game in this sector. But what impressed me is how they responded. Instead of sitting around, Pfizer acquired a biotech firm with a promising GLP-1 candidate and partnered with another pharma company on a GLP-1 pill. That's management showing they know how to adapt and survive long-term.

Here's the thing about Pfizer for income-focused investors: the company explicitly stated they plan to maintain their dividend at current levels even while navigating their challenges. That's a strong signal. And the numbers back it up - you're looking at a 6.3% yield, which is genuinely attractive in today's market. For anyone hunting for best weekly dividend stocks to build consistent income, Pfizer's actually worth serious consideration. The P/E ratio sits around 20, which feels way more reasonable than Lilly's valuation.

I get why people are chasing Eli Lilly. The GLP-1 space is hot, and Lilly's winning right now. But that's exactly when you need to be careful. The market's priced in perfection, and perfection rarely happens in pharmaceuticals. Competitors are actively developing their own GLP-1 drugs to challenge Lilly's dominance. Patent cliffs are real. And when you're paying 45 times earnings for a company with a 0.6% dividend, you're betting that everything goes exactly right.

Pfizer, meanwhile, is the overlooked play. Yes, it had a setback with its drug development. Yes, patent expirations are coming. But the company's showing it can pivot, it's protecting the dividend, and it's offering a yield that actually compensates you for being a shareholder. If you're building a portfolio of best weekly dividend stocks, mixing in some beaten-down pharma with real income potential makes sense.

Look, I'm not saying Eli Lilly's a bad company. I'm saying the price reflects a best-case scenario, and the dividend isn't going to help you if growth disappoints. Pfizer's different. It's unloved, it's yielding real income, and management is backing the dividend while they work through their headwinds. History shows that Wall Street eventually remembers these stories - and when it does, the upside could be substantial for patient investors who got in while sentiment was negative.

If you're serious about finding income-generating opportunities in pharma, take the time to dig into Pfizer. Sometimes the best stocks aren't the ones everyone's talking about.